A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs VS 4718 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Verastem
- 25 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2016 as reported by ClinicalTrials.